LU91181I2 - Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt). - Google Patents

Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).

Info

Publication number
LU91181I2
LU91181I2 LU91181C LU91181C LU91181I2 LU 91181 I2 LU91181 I2 LU 91181I2 LU 91181 C LU91181 C LU 91181C LU 91181 C LU91181 C LU 91181C LU 91181 I2 LU91181 I2 LU 91181I2
Authority
LU
Luxembourg
Prior art keywords
ziconotide
prialt
salt
optionally
pharmaceutically acceptable
Prior art date
Application number
LU91181C
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of LU91181I2 publication Critical patent/LU91181I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
LU91181C 1995-06-27 2005-07-06 Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt). LU91181I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (fr) 1995-06-27 1996-06-26 Compositions et formulations permettant de produire une analgesie et d'inhiber la progression de troubles lies a des douleurs neuropathiques

Publications (1)

Publication Number Publication Date
LU91181I2 true LU91181I2 (fr) 2005-09-06

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91181C LU91181I2 (fr) 1995-06-27 2005-07-06 Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).

Country Status (13)

Country Link
EP (2) EP1336409B1 (fr)
JP (1) JP2838073B2 (fr)
AT (2) ATE359086T1 (fr)
AU (1) AU695166B2 (fr)
CA (1) CA2224795C (fr)
DE (3) DE69637021T2 (fr)
DK (2) DK0835126T3 (fr)
ES (2) ES2283671T3 (fr)
FR (1) FR05C0027I2 (fr)
LU (1) LU91181I2 (fr)
NL (1) NL300201I2 (fr)
PT (2) PT1336409E (fr)
WO (1) WO1997001351A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
EP1054896A1 (fr) * 1998-02-20 2000-11-29 Zeneca Limited PEPTIDES ANALGESIQUES EXTRAITS DU VENIN DE LA $i(GRAMMOSTOLA SPATULATA) ET LEUR UTILISATION
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2386566A3 (fr) 2002-12-02 2012-02-15 Xenome Ltd Peptides de chi-conotoxine (II)
JP4565087B2 (ja) 2002-12-02 2010-10-20 ゼノム リミティッド 新規なχ−コノトキシン・ペプチド（−Ｉ）
SI2246360T1 (sl) 2003-01-28 2012-10-30 Ironwood Pharmaceuticals Inc Sestavki za zdravljenje gastrointestinalnih motenj
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
JP2010509209A (ja) * 2006-11-04 2010-03-25 エニジェン カンパニー リミテッド 新規なω−コノトキシン
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2373296B1 (fr) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
AU2009334511C1 (en) 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014029983A1 (fr) 2012-08-21 2014-02-27 Ardelyx, Inc. Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
PT2983667T (pt) 2013-04-12 2019-07-11 Ardelyx Inc Compostos e métodos de ligação ao nhe3 para inibir o transporte de fosfato
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (fr) * 1991-11-12 1993-05-27 Neurex Corporation Compositions pour le traitement retarde de lesions neuronales associees a l'ischemie
EP0625162B1 (fr) * 1991-12-30 1998-05-13 Neurex Corporation Procedes servant a induire l'analgesie et a favoriser l'analgesie par opiaces
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
CA2224795C (fr) 2001-04-03
ES2194998T3 (es) 2003-12-01
DE69637021T2 (de) 2008-01-10
DE122005000043I2 (de) 2006-08-03
NL300201I2 (nl) 2006-02-01
DK0835126T3 (da) 2003-07-14
JP2838073B2 (ja) 1998-12-16
ES2283671T3 (es) 2007-11-01
HK1058146A1 (en) 2004-05-07
EP1336409B1 (fr) 2007-04-11
EP0835126A1 (fr) 1998-04-15
DE69627153D1 (de) 2003-05-08
EP1336409A1 (fr) 2003-08-20
WO1997001351A1 (fr) 1997-01-16
DE122005000043I1 (de) 2006-06-29
PT835126E (pt) 2003-07-31
ATE235914T1 (de) 2003-04-15
DE69637021D1 (de) 2007-05-24
NL300201I1 (nl) 2005-09-01
CA2224795A1 (fr) 1997-01-16
EP0835126B1 (fr) 2003-04-02
FR05C0027I2 (fr) 2006-12-29
AU695166B2 (en) 1998-08-06
ATE359086T1 (de) 2007-05-15
JPH09104634A (ja) 1997-04-22
FR05C0027I1 (fr) 2005-08-12
DE69627153T2 (de) 2003-12-04
AU6400296A (en) 1997-01-30
PT1336409E (pt) 2007-06-29
DK1336409T3 (da) 2007-08-13

Similar Documents

Publication Publication Date Title
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU88746I2 (fr) Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU90234I2 (fr) Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine
FI925342L (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
LU91599I2 (fr) Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
EP0938328A4 (fr) Procede d'inhibition de la fibrose a l'aide d'un agoniste de somatostatine
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
CA2169071A1 (fr) Methodes pour moduler la reaction sexuelle chez l'espece humaine
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
EP1029540A3 (fr) Utilisation de la droloxifène pour le traitement de maladies cardiovasculaires
EP0664289A3 (fr) Isoquinoléines
AU1331588A (en) Method for treatment of alcohol abuse
EP0884326A3 (fr) Composé antithrombotique
FI850449A7 (fi) Menetelmä (-)-trans-4-(4-fluorifenyyli) -3-(4-metoksifenoksi)-metyylipiperidiinin tai sen farmaseuttisesti hyväksyttävien happoadditiosuolojen valmistamiseksi.
CA2301706A1 (fr) Utilisation de phanquinone dans le traitement de la maladie d'alzheimer
ITMI911880A1 (it) Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
EA199800102A1 (ru) Получение производных бициклогексана
EP1152762B8 (fr) Utilisation de desoxypeganine dans le traitement de la demence d'alzheimer
CA2260863A1 (fr) Traitement de troubles d'ordre psychotique
CA2065889A1 (fr) Augmentation du debit choroidien
CA2135752A1 (fr) Utilisation de la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine dans le traitement de la maladie d'alzheimer
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana